Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of elafibranor in adults with primary sclerosing cholangitis
2026-525242-29-00Phase 3Authorised
- Sponsor
- Ipsen
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing Elafibranor with Placebo (2 arms). Primary endpoint: Event-free survival. Planned start Aug 2026; status: authorised.
02
Drugs
elafibranor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2026-525242-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525242-29-00.